Pharmaceutical Business review

Telik Q3 net loss narrows

Loss from operations for third quarter of 2012 was $1.88m compared to loss from operations of $2.85m for the third quarter of 2011.

The company reported a net loss of $6.20m, or $3.07 per share, for the nine months ended 30 September 2012 compared to a net loss of $9.52m, or $5.30 per share, for the nine months ended 30 September 2011.

Loss from operations of $6.21m was reported for the first nine months of 2012 compared to loss from operations of $9.55m for the first nine months of 2011.